Description: Magnasense AB, a diagnostic company, develops and commercializes tests for monitoring and optimizing the dosage of biological drugs Sweden and internationally. The company focuses on the neurology, oncology, and autoimmune therapeutic areas. It offers moNATor, a first dose-monitoring laboratory test that provides multiple sclerosis for healthcare professionals and patients; and Viraspec, a COVID-19 saliva test kit. The company was formerly known as AegirBio AB (publ) and changed its name to Magnasense AB in July 2024. Magnasense AB was incorporated in 2019 and is headquartered in Lund, Sweden.
Home Page: www.magnasense.com
Scheelevägen 27
Lund,
223 63
Sweden
Phone:
46 4 62 86 54 00
Officers
| Name | Title |
|---|---|
| Mr. Marco Wititteveen | CEO & Member of the Board |
| Ms. Vicki Johnson | Interim Chief Financial Officer |
| Dr. Vasiliki Fragkou | Chief Operating Officer |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |